DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

Over 40 companies are working on more than 50 therapies for severe asthma. The severe asthma market is growing due to a ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

The growth of the severe asthma treatment market can be attributed to the increasing prevalence of asthma worldwide, coupled ...

A study published in JAMA reports on data showing that Combination ICS-SABA and ICS-Formoterol asthma treatments are more ...

Dr Harpreet Ranu discusses a new local severe asthma biologics service and its benefits for staff, patients and the wider ...

Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics ...

The study that Community Health Center patients, like Cridele, have been participating in seeks to alleviate the strain on rural patients by testing their lung performance at home, with a mobile ...

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero’s rating is based on ...

That may include avoiding triggers, taking allergy medication (antihistamines), or allergy shots (immunotherapy). Non-Allergic Asthma Between 10% and 33% of all people with asthma have non-allergic ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

but the new formulation will allow patients to take greater control of their treatment. Like its predecessor, it is approved in the EU for use in patients 12 years and older with severe asthma who ...